Looking good1 Jul 2024 07:01
Positive Data from SDC-1801 Phase 1 Clinical Trial
Cambridge, UK, 1 July 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage
biotechnology company developing next-generation kinase inhibitors for
autoimmune disease and cancer, is pleased to announce positive topline data
from its Phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase
inhibitor being developed as a potential new therapeutic for a range of
autoimmune diseases.
Following the dosing of the final cohort in the Multiple Ascending Dose stage
of the trial, and review of the initial data by the Safety Review Committee,
the Company reports that:
· Blood plasma levels of SDC-1801 significantly in excess of the
predicted therapeutic exposure were achieved, with a half-life of between 17
and 20 hours observed, which suggests that once-daily dosing will be possible*
· No deaths or serious adverse events due to SDC-1801 were reported
· Although data remains blinded, there appear to be no significant
changes in blood cell counts or increases in serum creatinine levels, which
may be dose limiting side-effects of brepocitinib, currently the most advanced
TYK2/JAK1 dual inhibitor
*Half-life is an estimation of the time it takes for an initial concentration
of SDC-1801 to be reduced by half in the body.
The Company expects that further data, unblinded from drug/placebo recipients,
including details of any mild or moderate adverse events and biomarkers of
TYK2 and/or JAK1 inhibition, will be available in Q3 2024.
Dr Tim Mitchell, Chief Executive Officer of Sareum, commented: "We are
delighted that the dosing of subjects in the SDC-1801 clinical trial has been
completed successfully and without any serious adverse events. We look forward
to building a strong data package to advance SDC-1801 to the next stage of its
development."
Dr John Reader, Chief Scientific Officer of Sareum, added: "The success of
this stage of the clinical trial demonstrates that high blood levels of a dual
TYK2/JAK1 kinase inhibitor can be achieved without serious side effects.
Together with the long half-life observed, we believe this potentially gives
SDC-1801 significant advantages over its competitors. We're grateful to the
volunteers who participated in this trial, and to the clinical staff who
enabled its timely completion."
- END -
Sign In
Follow the stocks
